Ondansetron and Retacrit drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ondansetron (ondansetron) and Retacrit (epoetin alfa-epbx). Common drug interactions include death among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Ondansetron and Retacrit. It is created by eHealthMe based on reports of 63 people who take the same drugs from the FDA, and is updated regularly.

What is Ondansetron?

Ondansetron has active ingredients of ondansetron. It is often used in nausea. eHealthMe is studying from 122,738 Ondansetron users. Check the latest studies of Ondansetron.

What is Retacrit?

Retacrit has active ingredients of epoetin alfa-epbx. eHealthMe is studying from 2,196 Retacrit users. Check the latest studies of Retacrit.

On Jul, 04, 2026

63 people who take Ondansetron and Retacrit together, and have interactions are studied.

Ondansetron and Retacrit drug interactions.

What are the common drug interactions of Ondansetron and Retacrit, by gender? *:

female:

Death
Diarrhoea
Blood disorder
Feeding disorder (when children refuse to eat certain food groups)
General physical health deterioration (weak health status)
Malaise (a feeling of general discomfort or uneasiness)
Mucosal inflammation (infection of mucous membrane)
Nasopharyngitis (inflammation of the nasopharynx)
Oral herpes (viral infection of mouth)
Pruritus (severe itching of the skin)

male:

Death
Thrombocytopenia (decrease of platelets in blood)
Neoplasm malignant (cancer tumour)
Pain
Malignant neoplasm progression (cancer tumour came back)
Rash erythematous (redness of the skin)
Hospitalisation
Emergency care
Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)
Blood calcium decreased

What are the common drug interactions of Ondansetron and Retacrit, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Cerebral haemorrhage (bleeding within the brain)
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)

50-59:

Blood disorder
Mucosal inflammation (infection of mucous membrane)
Nasopharyngitis (inflammation of the nasopharynx)
Oral herpes (viral infection of mouth)
Thrombocytopenia (decrease of platelets in blood)
Anaemia (lack of blood)
Anxiety
Back pain
Bronchopulmonary aspergillosis (lung disorder caused by aspergillus fungi)
Death

60+:

Death
Thrombocytopenia (decrease of platelets in blood)
Neoplasm malignant (cancer tumour)
Pain
Diarrhoea
Malignant neoplasm progression (cancer tumour came back)
Rash erythematous (redness of the skin)
Feeding disorder (when children refuse to eat certain food groups)
Hospitalisation
Pruritus (severe itching of the skin)

What are the existing conditions these people have? *

Anaemia (lack of blood): 14 people, 22.22%
Multiple Myeloma (cancer of the plasma cells): 10 people, 15.87%
Primary Myelofibrosis (primary disorder of the bone marrow): 9 people, 14.29%
Burkitt Lymphoma (cancer of the lymphatic system): 6 people, 9.52%
Primary Mediastinal Large B-Cell Lymphoma (primary mediastinal large b-cell cancer of the lymph nodes): 5 people, 7.94%
Pain: 5 people, 7.94%
Occipital Neuralgia (a condition characterized by chronic pain in the upper neck): 5 people, 7.94%
Gout (uric acid crystals building up in the body): 5 people, 7.94%
High Blood Pressure: 4 people, 6.35%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 4 people, 6.35%

* Approximation only. Some reports may have incomplete information.

Do you take Ondansetron and Retacrit?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously